Table 2

Characteristics of breast cancer patients carrying A-T splicing mutation 1066-6T→G

PatientAge at diagnosis, (years)Follow-up (months)Family historyaHistologyTNMbRadiotherapyc
Treatment volume/Total doseAcute toxicity (CTC)Late toxicity (LENT-SOMA)
EL69180Invasive ductalpT1c,pN0,M0Breast, 50.4 GyGrade IGrade I
HR35192Invasive ductalpT2(m),pN1biii,M0Breast, 50.4 Gy; periclavicular, 45 GyGrade IGrade 0
KS63130Invasive ductal; invasive tubularpT1c,pN0,M0Breast, 50.4 GyGrade IGrade 0
ME3624d1Invasive ductalpT2,pN1biii,M0Refused radiotherapy
EL5415e0Invasive ductalpTx,pN1biii,M0Breast, 52.2 Gy, periclavicular, 45 GyGrade IIGrade I
MW50343Invasive ductalpT1c,pN0,M0Breast, 54 GyGrade IGrade I
ES62Invasive tubularpT1c,pN0,M0None
74280Invasive ductalrcT0,pN1biii,M0Axillary/periclavicular, 50.4 GyGrade IGrade 0
  • a Family history is given as the number of first- and second-degree relatives with breast cancer.

  • b Tumors are characterized according to the TNM classification (68) with one patient (HR) harboring a multifocal carcinoma, and one (ES) suffering from a regional recurrence at 74 years.

  • c None of the A-T heterozygotes showed radiotherapy-related toxicities higher than grade II.

  • d,e Two patients died from cancer at age d 38 years and e 56 years.